Femasys Partners With Kebomed To Commercialize FemBloc Permanent Birth Control In France And Benelux Region

Author: Benzinga Newsdesk | September 25, 2025 09:05am

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Kebomed, a leading European distributor of medical devices and equipment, to commercialize FemBloc Permanent Birth Control in France and the Benelux region (The Netherlands, Belgium, and Luxembourg). With France representing the largest single-market opportunity for FemBloc in Europe, this collaboration significantly expands access to the only non-surgical permanent birth control option and represents a major milestone in Femasys' European growth strategy following recent CE mark approval.

Posted In: FEMY